SUBSCRIPTION AGREEMENTSubscription Agreement • June 30th, 2023 • Priveterra Acquisition Corp. • Pharmaceutical preparations
This SUBSCRIPTION AGREEMENT (this “Subscription Agreement”) is entered into on June __, 2023, by and among Priveterra Acquisition Corp., a Delaware corporation (the “Company”) and the undersigned subscriber (“Subscriber”).
The purpose of this agreement (this “Confirmation”) is to confirm the terms and conditions of the transaction (the “Transaction”) entered into between Seller, Priveterra and Target on the Trade Date specified below. The term “Counterparty” refers to...Otc Equity Prepaid Forward Transaction • June 30th, 2023 • Priveterra Acquisition Corp. • Pharmaceutical preparations
This Confirmation, together with the Pricing Date Notices, evidences a complete binding agreement between Seller, Priveterra and Target as to the subject matter and terms of the Transaction to which this Confirmation relates and shall supersede all prior or contemporaneous written or oral communications with respect thereto.
NOTE SUBSCRIPTION AGREEMENTNote Subscription Agreement • June 30th, 2023 • Priveterra Acquisition Corp. • Pharmaceutical preparations
This NOTE SUBSCRIPTION AGREEMENT (this “Note Subscription Agreement”) is entered into on [ · ], 2023, by and among AEON Biopharma, Inc., a Delaware corporation (the “Company”), Priveterra Acquisition Corporation, a Delaware corporation (“Priveterra”), and the Subscriber set forth on the signature page hereto (“Subscriber”).
PRIVETERRA SPONSOR, LLCSponsor Share Arrangement • June 30th, 2023 • Priveterra Acquisition Corp. • Pharmaceutical preparations
This letter agreement (the “Agreement”) is being made as of June 29, 2023, by and between ACM ASOF VIII Secondary-C LP (“Subscriber”) and Priveterra Sponsor, LLC (“Sponsor”). Capitalized terms used, but not otherwise defined herein, shall have the meaning given to them in the Subscription Agreement (as defined below).
PRIVETERRA SPONSOR, LLCSponsor Share Arrangement • June 30th, 2023 • Priveterra Acquisition Corp. • Pharmaceutical preparations
This letter agreement (the “Agreement”) is being made as of June 29, 2023, by and between Polar Asset Management Partners (“Polar”) and Priveterra Sponsor, LLC (“Sponsor”). Capitalized terms used, but not otherwise defined herein, shall have the meaning given to them in the Subscription Agreement (as defined below).
